BDBM528127 US11180484, Example 79::US11180484, Reference Example K::US11613527, Example RC4

SMILES COCc1nn(Cc2cnc(nc2)N2CCCC2)cc1C(=O)NCc1c(F)c(OC)ccc1-n1cnnn1

InChI Key InChIKey=GSFPQMPKJFXLTO-UHFFFAOYSA-N

Data  2 KI  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 528127   

TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataKi:  0.230nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataKi:  0.380nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  76nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XII(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: >4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  1.5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKallikrein-1(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: >4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  127nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XII(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: >4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma serine protease inhibitor(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  1.20E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  7.31E+3nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine protease 1(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: >4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: <10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKallikrein-1(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: >4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  127nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKallikrein-1(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50: >4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent